175 related articles for article (PubMed ID: 34910361)
21. Silencing of epidermal growth factor, latrophilin and seven transmembrane domain-containing protein 1 (ELTD1) via siRNA-induced cell death in glioblastoma.
Serban F; Daianu O; Tataranu LG; Artene SA; Emami G; Georgescu AM; Alexandru O; Purcaru SO; Tache DE; Danciulescu MM; Sfredel V; Dricu A
J Immunoassay Immunochem; 2017; 38(1):21-33. PubMed ID: 27379831
[TBL] [Abstract][Full Text] [Related]
22. Magnetic Resonance Elastography reveals effects of anti-angiogenic glioblastoma treatment on tumor stiffness and captures progression in an orthotopic mouse model.
Schregel K; Nowicki MO; Palotai M; Nazari N; Zane R; Sinkus R; Lawler SE; Patz S
Cancer Imaging; 2020 May; 20(1):35. PubMed ID: 32398076
[TBL] [Abstract][Full Text] [Related]
23. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
24. 18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma.
Nedergaard MK; Michaelsen SR; Urup T; Broholm H; El Ali H; Poulsen HS; Stockhausen MT; Kjaer A; Lassen U
PLoS One; 2015; 10(2):e0115315. PubMed ID: 25680186
[TBL] [Abstract][Full Text] [Related]
25. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.
Verhoeff JJ; van Tellingen O; Claes A; Stalpers LJ; van Linde ME; Richel DJ; Leenders WP; van Furth WR
BMC Cancer; 2009 Dec; 9():444. PubMed ID: 20015387
[TBL] [Abstract][Full Text] [Related]
26. Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme.
Qin Y; Takahashi M; Sheets K; Soto H; Tsui J; Pelargos P; Antonios JP; Kasahara N; Yang I; Prins RM; Braun J; Gordon LK; Wadehra M
J Neurooncol; 2017 Aug; 134(1):29-40. PubMed ID: 28597184
[TBL] [Abstract][Full Text] [Related]
27. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
[TBL] [Abstract][Full Text] [Related]
28. Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI.
Cho HR; Kumari N; Thi Vu H; Kim H; Park CK; Choi SH
Sci Rep; 2019 Jul; 9(1):11085. PubMed ID: 31366997
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
[TBL] [Abstract][Full Text] [Related]
30. MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.
Jalali S; Chung C; Foltz W; Burrell K; Singh S; Hill R; Zadeh G
Neuro Oncol; 2014 Jun; 16(6):868-79. PubMed ID: 24759636
[TBL] [Abstract][Full Text] [Related]
31. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
[TBL] [Abstract][Full Text] [Related]
32. ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression.
Sheldon H; Bridges E; Silva I; Masiero M; Favara DM; Wang D; Leek R; Snell C; Roxanis I; Kreuzer M; Gileadi U; Buffa FM; Banham A; Harris AL
Mol Cancer Res; 2021 Nov; 19(11):1957-1969. PubMed ID: 34348993
[TBL] [Abstract][Full Text] [Related]
33. Novel Targeting of Transcription and Metabolism in Glioblastoma.
Su YT; Chen R; Wang H; Song H; Zhang Q; Chen LY; Lappin H; Vasconcelos G; Lita A; Maric D; Li A; Celiku O; Zhang W; Meetze K; Estok T; Larion M; Abu-Asab M; Zhuang Z; Yang C; Gilbert MR; Wu J
Clin Cancer Res; 2018 Mar; 24(5):1124-1137. PubMed ID: 29254993
[No Abstract] [Full Text] [Related]
34. Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration.
Bazan NG; Reid MM; Flores VAC; Gallo JE; Lewis W; Belayev L
Cancer Metastasis Rev; 2021 Sep; 40(3):643-647. PubMed ID: 34519960
[TBL] [Abstract][Full Text] [Related]
35. Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments.
Achyut BR; Shankar A; Iskander AS; Ara R; Knight RA; Scicli AG; Arbab AS
Cancer Biol Ther; 2016; 17(3):280-90. PubMed ID: 26797476
[TBL] [Abstract][Full Text] [Related]
36. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
37. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
38. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
[TBL] [Abstract][Full Text] [Related]
39. Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.
Kratzsch T; Kuhn SA; Joedicke A; Hanisch UK; Vajkoczy P; Hoffmann J; Fichtner I
J Cancer Res Clin Oncol; 2018 May; 144(5):809-819. PubMed ID: 29427211
[TBL] [Abstract][Full Text] [Related]
40. Evolving strategies: future treatment of glioblastoma.
Chamberlain M
Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
